Revium RX

Revium Rx, Inc. (OTC: RVRC), formerly known as Revium Recovery Inc. before the company's strategic transformation in early 2025, is a pre-clinical biopharmaceutical company focused on the development of nano-medicine platforms to deliver advanced treatment solutions for diseases with limited or no effective treatment options. The company completed the acquisition of LipoVation Ltd., an Israeli development-stage company specializing in lipid-based nano and micro particle medicine technologies, in February 2025 — a strategic transaction that substantially redirected the company's focus toward nanoparticle-based therapeutics. LipoVation's expertise in lipid nanoparticle formulation technology is directly relevant to Revium Rx's therapeutic development pipeline, as lipid nanoparticle delivery systems have emerged as one of the most clinically validated drug delivery platforms following their central role in the mRNA COVID-19 vaccines developed by Moderna and BioNTech/Pfizer.<br><br>Revium Rx is developing two principal product candidates from its nano-medicine platform: a liposomal antibiotic formulation targeted at combating drug-resistant bacterial infections, where conventional antibiotics have become increasingly ineffective due to widespread antimicrobial resistance; and a liposomal cancer therapy designed to enhance the impact and efficacy of existing cancer treatments by delivering therapeutic agents more precisely to tumor cells using lipid nanoparticle encapsulation technology. Both product candidates are in early stages of development and have not yet been approved for clinical trials by the FDA or other regulatory authorities, reflecting the pre-clinical status of the company's pipeline. Drug-resistant infections and cancer treatment inadequacy represent two of the most significant unmet medical needs in modern medicine, creating large potential markets for effective nano-medicine solutions if clinical development programs successfully establish safety and efficacy.<br><br>Revium Rx, Inc. trades on the OTCID tier operated by OTC Markets Group under the ticker symbol RVRC and has filed a Form S-1 registration statement with the Securities and Exchange Commission. The company intends to apply to upgrade its common stock from the OTCID tier to the OTCQB Venture Market as it progresses its business development and capital raising activities. The lipid nanoparticle drug delivery field has seen extraordinary scientific and commercial validation in recent years, and Revium Rx's acquisition of LipoVation positions the company to apply this established delivery technology to antibiotic resistance and oncology treatment enhancement — two therapeutic areas where nano-medicine approaches may offer meaningful clinical advantages over conventional drug formulation strategies.